Actively Recruiting
A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery
Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2025-04-02
40
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor
A
Affiliated Wenling Hospital of Wenzhou Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To observe and study the clinical effect of Huperzine A Injection on reducing postoperative delirium in elderly patients undergoing non-cardiac surgery
CONDITIONS
Official Title
A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 75 years old or older
- Scheduled for non-cardiac surgery under general anesthesia
- Anesthesia grade of American Society of Anesthesiologists (ASA) III to IV
- Estimated operation time of 2 hours or longer
- Voluntarily signed the informed consent form
You will not qualify if you...
- Impaired renal function with creatinine 1.5 times above normal lab limit
- Abnormal liver function with ALT and AST levels 2 times above normal lab limit
- Positive for infectious diseases
- Central nervous system injury
- History of delirium, epilepsy, or long-term use of psychoactive drugs
- Diseases with drug contraindications, bronchial asthma, mechanical intestinal or urinary tract obstruction
- Serious systemic diseases, especially circulatory diseases such as myocardial infarction, heart failure, angina, or sinus bradycardia
- Known allergy to narcotic drugs or Huperzine A Injection
- Use of incompatible drugs with Huperzine A Injection
- Participation in other clinical trials within 3 months
- Inability to tolerate tests or cooperate with examinations
- Aphasia, audio-visual dysfunction, or other conditions making participation unsuitable
- Investigator judgment deeming patient unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study
Wenzhou, Zhejiang, China, 325000
Actively Recruiting
Research Team
T
Ting Li, MD. PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here